S
Overview
Sentec is a medical device company focused on respiratory care, developing non-invasive monitoring and therapeutic tools for patients across care settings. Its system uses non-invasive sensors and data analytics to monitor respiratory parameters in real time and deliver targeted therapy when needed. It differentiates itself through a deep-tech, science-driven approach and a Swiss-American global footprint, offering precise measurements and clinically actionable solutions across care areas. Its goal is to improve respiratory patient outcomes by providing accurate monitoring and effective therapies for clinicians worldwide.
Work here?Claim your company
Simplify's take
What believers are saying
- Sentec launched tCOM+ updates September 2026, improving usability and sleep-lab adoption.
- The February 2026 European Service Centre shortens installs and supports customer retention.
- LuMon's first-in-class U.S. indication for premature infants creates a differentiated sales wedge.
What critics are saying
- The Phasitron 5 Class I recall remains open, threatening hospital trust through 2026.
- FDA warned October 2026 of IPV-ventilator leaks causing hypoventilation, acidosis, and respiratory failure.
- A repeat neonatal safety failure could freeze purchases and cripple Sentec's respiratory franchise.
What makes Sentec unique
- Sentec owns transcutaneous CO2 monitoring, centered on tCOM+ and V-Sign sensors.
- LuMon EIT, cleared September 4, 2025, extends noninvasive lung monitoring beyond CO2.
- PulmoTech integration adds esophageal pressure monitoring, broadening titration workflows for ventilated patients.
Help us improve and share your feedback! Did you find this helpful?